Latest Breaking News On - Mariusz olejniczak - Page 5 : comparemela.com

WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas

Share: WPD Pharmaceuticals Inc. (CSE:WBIO)(FSE: 8SV1) (the Company or WPD ) a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10 th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021. During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: New approach to glioblastoma treatment addressing the critical unmet medical need , granted by National Research and Development Center ( NRDC ) and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020.

United statesNew yorkUnited kingdomBritish columbiaMariusz olejniczakThomas renaudMoleculin biotech incSociety of pediatric oncologyNational researchSmart growth operational programNeither the canadian securities exchangeEuropean unionPharmaceuticals incWake forest universityInvestment decisionsUniversity of texas md anderson cancer center

WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates

WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

United kingdomBritish columbiaMoleculin annamycinMariusz olejniczakMoleculin biotech incNeither the canadian securities exchangeInvestment industry regulatory organization of canadaPharmaceuticals incWake forest university health sciencesWake forest universityMoleculin biotechNext generation anthracyclineTranscription modulatorTranscription modulatorsCanadian securities exchangeInvestment industry regulatory organization

WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101

WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

David walkerProf walkerBrain cancerPaediatric oncologyDrug deliveryUniversity of nottinghamMariusz olejniczakClinical stageடேவிட் வாக்கர்ப்ரொஃப் வாக்கர்மூளை புற்றுநோய்குழந்தை புற்றுநோயியல்மருந்து டெலிவரிபல்கலைக்கழகம் ஆஃப் நாட்டிங்ஹாம்மரியஸ் ஒளேஜ்ணிக்ஜக்மருத்துவ நிலை

WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Mariusz olejniczakReata pharmaceuticalsWpd sublicensed berubicinClinigen clinical supplies managementமரியஸ் ஒளேஜ்ணிக்ஜக்றேதத மருந்துகள்

WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

Share this article HOUSTON, Feb. 18, 2021 /PRNewswire/ WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ( WPD ) and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ( CNS or the Company ), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD Pharmaceuticals received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Muliforme (GBM) under the WPD-201 Clinical Trial Protocol. CNS Pharmaceuticals has received study level Central IRB Approval from the Central IRB for the CNS-201 Clinical Trial Protocol.

United statesMariusz olejniczakJohn climacoMoleculin biotech incMd anderson cancer centerSmart growth operational programEuropean unionEthics committeePharmaceuticals incWake forest universityOffice for registration of medicinal productsCentral ethics committeeNational centerCompetent authorityDrug administrationWake forest university health sciences